Lessons From Ebola: FDA Floats New Paradigm For Testing Drugs In Emergencies
This article was originally published in The Pink Sheet Daily
Adaptive, randomized trial design could be model for therapies aimed at other emerging diseases, such as MERS-CoV, officials write in New England Journal of Medicine.
You may also be interested in...
Update to 2005 outline of US response to pandemic influenza was due at the end of 2016, but has yet to be released.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.